Redefined Life Group Switzerland

Benign prostatic hyperplasia (BPH) is a common condition in older men, characterized by an enlarged prostate that can cause urinary obstruction. Transrectal ultrasound (TRUS) is an effective tool for assessing prostate volume and structure, providing valuable information for BPH management.

TRUS enables clinicians to measure the size of the prostate accurately and evaluate the degree of urethral compression. This helps determine the severity of urinary obstruction and guides decisions on medical therapy versus surgical intervention.

In addition, TRUS can identify the presence of nodules or cysts that may contribute to symptoms. Understanding the prostate’s internal architecture allows for personalized treatment planning, such as selecting the appropriate minimally invasive procedure or medication.

TRUS is also useful for monitoring response to treatment over time. By repeating the procedure periodically, clinicians can track changes in prostate size and adjust therapy as needed. Its safety, non-invasive nature, and detailed imaging make it an essential…

Pharmacological treatments are central to managing hyperkalemia, offering precise ways to lower elevated potassium levels while minimizing risks. Medications are selected based on the severity of hyperkalemia, kidney function, and the urgency of correction.

Intravenous calcium salts stabilize the cardiac membrane, protecting the heart from potassium-induced arrhythmias. Though they do not remove potassium, they are often the first step in treatment, buying time for other interventions.

Potassium shifts into cells are promoted by insulin-glucose therapy and beta-agonists. Insulin drives potassium intracellularly, while inhaled beta-agonists stimulate similar uptake. Both methods act rapidly, making them ideal for acute care.

Diuretics increase renal potassium excretion when kidney function is adequate. Loop diuretics are particularly effective, enhancing urinary potassium elimination while supporting fluid balance. In chronic kidney disease or cases of impaired renal function, potassium binders are preferred. Newer agents, including patiromer and sodium zirconium cyclosilicate, remove potassium through the gut, providing a slower…